Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Medical management options for heavy menstrual bleeding, as recommended by NICE, include: Levonorgestrel intrauterine system (LNG-IUS) : Often first-line treatment, reducing menstrual blood loss by up to 95% within 12 months Tranexamic acid : An antifibrinolytic agent taken during menstruation to reduce blood loss by 40-50% (caution if you have a history of blood clots) Non-steroidal anti-inflammatory drugs (NSAIDs) : Such as mefenamic acid, which can reduce flow by 20-30% and help with associated pain (use with caution if you have gastrointestinal, renal or cardiovascular conditions) Combined hormonal contraception : Can regulate cycles and reduce bleeding in suitable candidates Oral progestogens : Taken cyclically or continuously, depending on individual circumstances If you currently use a copper intrauterine device (IUD), this can contribute to heavier periods, and switching to a levonorgestrel IUS might be beneficial
van Boxel EJ et al
Current literature suggests that the L-carnitine system is perturbed in AD, with multiple studies showing that proteins and metabolites related to the L-carnitine system are altered in the brain, CSF, and plasma of AD patients (Toledo et al., 2017
doi: 10.7326/0003-4819-128-3-199802010-00001
Every dose in the standard escalation schedule fits within a 100-unit syringe
El medicamento Wegovy, con el mismo principio activo que Ozempic, la semaglutida, ha sido desarrollado para el tratamiento de la obesidad y el sobrepeso con factores de riesgo
US$ 24.41
US$ 27.79
US$ 22.02
